Novartis to sell OTC business to GSK Consumer for $17.6m
The move follows a deal signed in April 2014, under which Novartis had agreed with GSK to create a global consumer healthcare JV as part of its global
Novartis has begun construction on its new 46,000ft² radioligand therapy (RLT) manufacturing facility in Denton, Texas, marking the latest step in its $23bn investment in US manufacturing and research.
Axxess Pharma anticipates Canadian pharmacies expanding the TapouT line of products on their shelves. The expansion is anticipated to include TapouT supplement and protein categories, such as TapouT
The research agreement will identify targets for this therapy in myelodysplastic syndrome (MDS), a bone marrow disorder in which the body does not produce sufficient healthy blood cells.